News Standigm selects CDD Vault to augment its Drug Discovery AI technology
The hosted informatics platform will facilitate the advancement of Standigm’s collaborative drug discovery projects
News SK invests in Standigm for AI-based drug development
HONG KONG – SK Holdings Co. Ltd. invested KRW10 billion (US$8.6 million) in Standigm Inc., an artificial intelligence (AI)-powered biotech company based in Seoul, Korea. It is the second big investment Standigm has attracted this year after a KRW13 billion series B round in March.
Event BIO International Convention 2019
Date : June 3-6, 2019
Location : Philadelphia, PA, USA
Jinhan Kim, Standigm CEO is supposed to attend the BIO International Convention 2019.
News Standigm Raises US $11.5 Million in Series B Round Funding to advance its AI-powered drug pipelines toward license-out
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised 11.5 million dolloar in a Series B funding round led by Mirae Asset Venture Investment and Mirae Asset Capital. Standigm will use the funds to scale the AI technology platforms and advance its drug discovery pipelines toward license-out. The new round brings Standigm’s total financing to $15 million.
News Standigm is developing incurable disease drugs with AI, in collaboration with big pharma
Standigm is developing drugs for NASH, Parkinson, autism.